We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 7.960-0.4%Oct 22 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (3226)11/20/2012 10:45:08 AM
From: richardred  Read Replies (3) of 6087
Bayer should be looking after being rebuffed.

Cyanotech Corp. (CYAN) looks interesting and has come down greatly. Insiders own a big chunk. It's on the watch list already but speculative appeal has gone up IMO. On the downside Cyanotech is a very small company which might limit its appeal.
Health and nutrition has been a good target for acquirers. RE: Martek Biosciences and more recently, the $11.9 billion acquisition of Pfizer Inc.’s infant-nutrition unit by Nestles.
DSM (NYSE Euronext: DSM KON) recently acquire Fortitech for total enterprise value of USD 634 million (about €495 million) in cash. (DSM bought my Martek).
DuPont Acquires Enzyme Maker Danisco for $5.8 Billion
I had Weider Nutrition (now Shiff) on the watch list when I owned Martek, but OH Well.
I currently own SunOpta Inc. (STKL) for health and nutrition.

Bayer shuns bidding war with Reckitt over Schiff

Tue Nov 20, 2012 6:56am EST

* Bayer: Outbidding Reckitt wouldn't meet its M&A criteria

* Says to continue looking for bolt-on acquisitions

* Reckitt offered $1.4 bln, above Bayer's $1.2 bln

FRANKFURT, Nov 20 (Reuters) - German drugmaker Bayer AG gave up trying to buy Schiff Nutrition after Reckitt Benckiser made a higher offer for the U.S. vitamin maker.

"Bayer AG's Board of Management has decided not to propose any increase" to its offer, the group said in a filing with the U.S. Securities and Exchange Commission published on Tuesday.

Reckitt trumped Bayer's agreed $1.2 billion deal to buy Schiff with an offer of $1.4 billion for the U.S. vitamin maker.

"Entering a competitive bidding process in response to the November 18 Proposal (Reckitt's bid) would result in a price outside Bayer's set financial criteria," the filing said.

Bayer plans to continue its strategy to augment organic growth with strategic bolt-on acquisitions, it added.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext